Index

Page numbers in *italics* denote figures, those in **bold** denote tables.

A blood group **336**
AB blood group **336**
abciximab **319**, 320
ABO blood group system 334–5, *336*, **336**, *337*
  antibodies 334, **336**
  haemolytic disease of newborn 352
  and venous thrombosis 306
ABVD regimen 211
acanthocytes *23*
acanthocytosis *325*
aciclovir 259
acquired haemolytic anaemias 68–71
  chemical and physical agents 71
  immune 68–70, **68**, *69*, *70*
  infections 71
  march haemoglobinuria 70
  red cell fragmentation syndromes 70, *70*, **70**
actin 19
activated partial thromboplastin time (aPTT) 276, **276**
  coagulation disorders **294**, **299**
activated protein C (APC) 275, *275*, 304
activation domain 8
acute hyperviscosity syndrome 221
acute lymphoblastic leukaemia (ALL) 186–96
  BCR-ABL1 positive 194–5
  classification 188, **188**, **189**
  clinical features 188, *188*, *189*
  CNS-directed therapy 193
  cytogenetics/molecular genetics 189–91, *190*, *191*
  immunological markers **189**
  incidence and pathogenesis 187, *187*
  intensification (consolidation) therapy 192–3
  investigations 188–9, *189*, **189**
  maintenance therapy 193–4
  minimal residual disease 192, *193*
  prenatal origin *187*
  prognosis **194**, 196, *195*
  relapse *193*, 194
  remission induction 192
  specific therapy 192, *192*, 194
  supportive therapy 192
  toxicity of therapy 194
acute myeloid leukaemia (AML) 145–55
  blood film *150*
  classification **146**, 147–8
  clinical features 148, *148*, *149*
  cytogenetics/molecular genetics **146**, 149, *151*, **151**, *152*
  incidence 147
  investigations 148–9, **149**
  older patients 153
  outcome 154, *155*
  pathogenesis 147, *147*
  prognosis **151**, 153
  relapse 154
  stem cell therapy 153
  treatment 149, 151–3, *152–4*
acute promyelocytic leukaemia 149
  treatment 152–3
ADAMTS13 267, 285, *285*, 286
adaptive immune system 88
adhesion molecules 8
adriamycin **142**
  BEACOPP regimen 211
adult T-cell leukaemia/lymphoma *203*, 204, 226
African iron overload 43
age effects *see* older patients
AIDS *see* HIV/AIDS
Alder's anomaly *93*
alemtuzumab **143**
  aplastic anaemia 246
  CLL 201
alkylating agents 140, *141*, **142**
  see also individual drugs
ALL *see* acute lymphoblastic leukaemia
all-trans retinoic acid (ATRA) *141*, 144, 152
  ATRA syndrome 153
allele-specific priming 85
allergic reaction to blood transfusion 342
allogeneic stem cell transplantation 236, 255–62
  chimaerism analysis 256
  complications 256–61, **258**
  donor leucocyte infusions 261, *262*
  graft failure 260
  graft-versus-leukaemia effect 261, *261*
  HLA system 255–6, *255*, **256**
  post-transplant lymphoproliferative diseases 261–2, *262*
alloimmune haemolytic anaemias 70
alternative complement pathway 109, *109*
amegakaryocytic thrombocytopenia 244
aminocaproic acid 280
γ-aminolaevulinic acid 16, 29
AML *see* acute myeloid leukaemia
amplification enzyme system 109
amplifications 130
amyloidosis 23–9, **239**, *239*
anaemia 19–25, **20**
  aplastic 91, 243–7
  blood film 22–3, *23*
  bone marrow in 23–4, *24*
  of chronic disorders 37, **37**, **38**, 322, **322**
  classification **22**
  clinical features 20–1, *21*
  congenital dyserythropoietic 249
  global incidence 19–20
  haemolytic *see* haemolytic anaemias
  HIV/AIDS 328
  hypochromic 27–40, *28*
  ineffective erythropoiesis 24–5, *25*
  iron deficiency 32–7
  laboratory findings 33, **38**
  lead poisoning 39
  leucocyte and platelet counts 22
  macrocytic 49, 58–9, **58**
  malignant disease 322, *323*
  megaloblastic *see* megaloblastic anaemia
  microangiopathic haemolytic *70*, 322
  neonate 349–50, *349*
  older patients 322
  pernicious 52–3, **53**
  pregnancy 347, *347*
  of prematurity 350
  red cell indices 21
  refractory **178**
  renal failure 325, *325*
  sideroblastic 38–9, *38*, **38**, **39**
  see also specific types
anaplastic large cell lymphoma 226
androgens in aplastic anaemia 246
aneuploid cells 127
angioimmunoblastic lymphadenopathy 226
angular cheilosis *34*, *54*
ankyrin 19
anthracyclines *141*, **142**

COPYRIGHTED MATERIAL

anti-emetics in haematological malignancies 137
antibiotics 139
  cytotoxic **142**, 143
antibody-dependent cell-mediated cytotoxicity 106
anticardiolipid antibodies **307**
anticoagulants 312–18, *312*
  direct-acting parenteral 315
  heparin **299**, 312–15, **313**
  oral 315–18, **315–17**
  vitamin K antagonists 315–18, **315–17**
  see also specific drugs
antigen-presenting cells (APCs) 109
antigen-receptor gene rearrangements 107, *107*, *108*
antigenic specificity 103
antiglobulin test 65, 340, *340*
antihaemophilic factor *see* factor VIII
antihuman globulin 340
antimetabolites 141, *141*, **142**, 143
antiphospholipid syndrome 307
antiplatelet drugs 287, 318–20, *319*, **319**
antithrombin deficiency 305
antithymocyte globulin 246
antiviral drugs 139
apixaban **317**, 318
aplastic anaemia 91, 243–7, *243*
  causes **243**
  clinical features 245–6, *245*
  congenital (Fanconi anaemia) 244, *244*
  diagnosis 246
  idiopathic acquired 244
  laboratory findings 246
  pathogenesis 244
  secondary causes 245
  treatment 246–7
apoptosis 9–10, *9*
argatroban 315
arsenic **143**, 144
arterial thrombosis 303, *303*, **303**
Ashwell-Morell receptor 266
asparaginase *141*, **143**, 144
aspergillosis 139–40, *139*, *140*
aspirin 319, **319**
  platelet function disorders 287, *288*
  polycythaemia vera 171
atherosclerosis *see* arterial thrombosis
ATRA syndrome 153
atrophic gastritis 33, 35, 37, 53
Auer rods *150*
autoimmune gastritis 35, 52
autoimmune haemolytic anaemias 68–70, *69*
  classification **68**
  cold 69–70
  warm 68–9, *69*
autoimmune (idiopathic) thrombocytopenic purpura 282–3, *282*
  see also idiopathic thrombocytopenic purpura
autologous blood transfusion 343–4
autologous stem cell transplantation 254, *255*
automated blood cell counter *12*
autotransfusion 343–4
azacytidine **142**
  myelodysplasia 184
azathioprine *141*

B blood group **336**
B cells 103–4
  functional aspects **105**
  immunodeficiency **113**
B-cell chronic lymphoid leukaemias 198–203
B-cell prolymphocytic leukaemia 202, *202*
B-cell receptor 104, *105*
bacterial infections
  in cancer patients 138–9
  haematological changes 327–8
  and haematological malignancies 125
  transfusion-related **339**, 342
band neutrophils 89, *89*
Barr bodies 94
basket cells *23*
basophil leucocytosis (basophilia) 97
basophils **12**, 88, *88*, 90
  blood count **20**, **88**
BCL-2 9
BCR-ABL inhibitors **142**, 143
BCR-ABL1 mutation 161, 187, 194–5
BEACOPP regimen 211
Bence-Jones protein 232
bendamustine **142**
benign ethnic neutropenia 95
Bernard-Soulier syndrome 266, 287
bilirubin 61
biopsy of bone marrow 24, *24*, **25**
bisphosphonates 237
bivalirudin 315
blackwater fever 329
bleeding disorders 278–89
  abnormal bleeding 279, **279**
  thrombocytopenia *see* thrombocytopenia
  vascular 279–80, **279**
bleeding time 277
bleomycin *141*, **142**, 143
  BEACOPP regimen 211
blood cells 12, *12*, **12**, *13*
  count *see* blood count
  see also red cells; white cells
blood coagulation *see* coagulation
blood components 343–5, *343*
blood count **20**, **88**, 276
  see also specific cell types
blood disorders and venous thrombosis 307
blood donors 334, **335**
  see also blood transfusion
blood film 276
  acute myeloid leukaemia *150*
  adult T-cell leukaemia/lymphoma *203*
  ALL *190*
  anaemia 22–3, *23*
  autoimmune haemolytic anaemia *69*
  B-cell prolymphocytic leukaemia *202*
  β-thalassaemia major *79*
  CLL *199*
blood film CML, *159*, *163*
  diffuse large B-cell lymphoma *224*
  eosinophilic leucocytosis *97*
  G6PD deficiency *67*
  hairy cell leukaemia *203*
  hereditary spherocytosis *65*
  iron deficiency 34, *34*, *35*
  large granular lymphocytic leukaemia *203*
  liver disease *325*
  lymphocytosis *112*
  malignant disease *323*, *324*
  mantle cell lymphoma *223*
  megaloblastic anaemia *55*
  microangiopathic haemolytic anaemia *70*
  multiple myeloma *235*
  myelodysplasia *183*
  myelofibrosis *174*
  non-Hodgkin lymphoma *218*
  renal failure *325*
  sickle cell anaemia *84*
  splenic atrophy *117*
  thrombocythaemia *173*
  thrombotic thrombocytopenic purpura *286*
blood groups
  antibodies 334, **336**
  determination of 340, *340*
  serology 339–40
  see also individual blood groups
blood loss *see* haemorrhage
blood products
  haematological malignancies 136–7
  irradiated **342**
  post-stem cell transplant 259
  reduction of use 342–3
  see also blood transfusion

blood salvage 344
blood transfusion 333–45, *334*
  autologous 343–4
  bacterial contamination 342
  blood group serology 339–40
  complications 340–2, **341**
  cross-matching and pre-transfusion tests 340, *340*, **341**
  hazards of 338–9, **338**, **339**
  iron overload 44, *44*, *45*, 342
  massive transfusion syndrome 287
  post-transfusion purpura 284, 342
  protection of recipient **338**
bone morphogenetic protein (BMP) 30
bone marrow 2, *2*
  ALL 188
  anaemia 23–4, *24*
  biopsy 24, *24*, **25**
  failure *245*
  HIV/AIDS *329*
  iron stores 34, *35*
  myelodysplasia 180
  pluripotent stem cells *3*
  red cell aplasia *247*
  stroma 4, *4*
  transplantation 251
  trephine biopsy 24, *24*, **25**
Borrelia burgdorferi **339**
bortezomib *141*, 143, **143**
  mantle cell lymphoma 223
  multiple myeloma 237
  VMP regimen 235
bosutinib **142**, **160**
bridging anticoagulation 316–17
Brucella melitensis **339**
Burkitt lymphoma 224–5, *225*
  cytogenetics **217**
  immunophenotype **217**
burr cells *325*

C-reactive protein 332
C282Y mutation 43
CALR (calreticulin) mutation 166, *167*, **172**
Candida infections in cancer patients 140
CAR (chimeric antigen receptors) 194
carfilzomib **143**
  multiple myeloma 235, 237
caspases 9
CD2 **189**
CD3 **189**
CD7 **189**
CD10 **189**
CD11c **147**
CD13 **147**
CD14 **147**
CD19 **189**, 194
CD20 antibodies 201
CD22 **189**
CD33 **147**
CD39 270
CD41 **147**
CD42 **147**
CD52 antibodies 201
CD61 **147**
CD64 **147**
CD79a **189**
CD117 **147**
Cdks 8
CDT regimen 235
cell cycle 8
central nervous system lymphoma *224*, 225
central venous catheters 136, *136*
centroblasts 111
centromere 128, *129*
cerebral lymphoma *224*, 225
checkpoints 8
Chédiak-Higashi syndrome *93*, 94, 95
chelation therapy 45–7, *46*
chemical exposure
  acquired haemolytic anaemias 71
  haematological malignancies 124
chemokines 92–3
chemotaxis 92
  defects 93
children
  blood count **88**
  Burkitt lymphoma 224–5, *225*
  haemolytic uraemic syndrome 286
  iron requirements **33**
  juvenile myelomonocytic leukaemia 184
  myelodysplasia **178**
  sites of haemopoiesis **2**
  see also neonates
chimaerism 256
chimeric antigen receptors (CAR) 194
chlorambucil **142**
2-chlorodeoxyadenosine **142**
CHOP regimen 223
Christmas disease *see* haemophilia B (Christmas disease)
Christmas factor *see* factor IX
chromosomes 127–9, *128*, *129*
chronic disorders, anaemia of 37, **37**, **38**, 322, **322**
chronic eosinophilic leukaemia 164
chronic lymphocytic leukaemia (CLL) 198–202
  classification **198**
  clinical features 198–9, *198*, *199*
  course 202
  cytogenetics **217**
  immunophenotype **200**, **217**
  laboratory findings 199–200, *199*
  molecular tests 200, **200**
  pathogenesis 198
  prognosis **202**
  staging 200, **201**
  treatment 200–2
chronic lymphoid leukaemias 197–204
  B-cell 198–203
  diagnosis 198
  T-cell 203–4
  see also specific types
chronic myeloid leukaemia (CML) 156–64, **157**
  accelerated phase disease 162–3
  atypical 184
  clinical features 159
  genetic mutations **166**
  laboratory findings 159, *159*
  Philadelphia chromosome *157–8*
  prognostic scores 159
  stem cell therapy 162, *163*
  treatment 160–2, *160–3*, **160**, **162**
chronic myelomonocytic leukaemia 180, 184
chronic neutrophilic leukaemia 164
ciclosporin
  aplastic anaemia 246
  CLL 201
cidofovir 259
classical complement pathway 109, *109*
clg **189**
CLL *see* chronic lymphocytic leukaemia
clofarabine **142**
clonal abnormalities **128**
clonal progression 125, 127, *127*
clopidogrel 287, *288*, **319**, 320
Clostridium perfringens 328, *328*
CNS *see* central nervous system
coagulation 270–3
  amplification 272–3, *272*
  in vivo 270–1
  initiation 271
  physiological limitation 274
  see also haemostasis
coagulation cascade 270, *271*
coagulation disorders 290–301
  acquired 296–301, **296**
  circulating antibodies 300–1
  disseminated intravascular coagulation 287, 297–300, *298*
  haemophilia A 291–5

coagulation disorders (*continued*)
haemophilia B (Christmas disease) **293**, **294**, 295
hereditary 291–6, *291*
liver disease 297
malignant disease 322–3, **324**
massive transfusion syndrome 287, **299**, 301
renal failure 326
von Willebrand disease **294**, 295–6, **295**
coagulation factors **271**, **273**
assays 277
circulating antibodies 300–1
inhibitors 275
vitamin K deficiency 296–7, *297*
see also specific factors
cobalamin 49
cold autoimmune haemolytic anaemias 69–70
colony-stimulating factor (CSF) *90*
colorectal carcinoma *36*
complement 109, *109*
compression paraplegia 237
compression ultrasound 308
computed tomography *see* CT
conditioning of stem cells 253
congenital dyserythropoietic anaemia 249
congestive heart failure 326
conjunctival pallor *21*
connective tissue disorders 279
haematological changes *324*
see also specific conditions
contrast venography 308
Coombs' test 65, 340, *340*
cords of spleen 117, *117*
corticosteroids **142**, 143
idiopathic thrombocytopenic purpura 283
coumarins *see* warfarin
Coxiella burnettii **339**
CRAB acronym 231
Creutzfeldt-Jacob disease 339, **339**
cross-matching of blood 340, *340*
cryoprecipitate 344
CT
multiple myeloma *233*
non-Hodgkin lymphoma *219*, *220*
CT pulmonary angiography 309, *309*
cyclin-dependent protein kinases *see* Cdks
cyclins 8
cyclophosphamide **142**
BEACOPP regimen 211
CHOP regimen 223
CLL 200
R-CVP regimen 222
cytogenetics
ALL 189–91, *190*, *191*
AML **146**, 149, *151*, **151**, *152*
Burkitt lymphoma **217**
CLL **217**
diffuse large B-cell lymphoma **217**
follicular lymphoma **217**
hairy cell leukaemia **217**
lymphoma **217**
lymphoplasmacytic lymphoma **217**
MALT lymphoma **217**
mantle cell lymphoma **217**
myelodysplasia **179**
cytokinesis 8
cytomegalovirus infection
haematological changes 328
post-stem cell transplant 259
transfusion-related 338
cytosine arabinoside *141*, **142**
cytotoxic drugs 140–3, *141*, **142–3**

D-dimer 277
deep vein thrombosis 308
pulmonary embolus 309
dabigatran **317**, 318
dasatinib **142**, **160**
daunorubicin **142**
DDAVP 267, 293–4, 296
decitabine **142**, 184
deep vein thrombosis 308, **308**
prophylaxis 318
see also thrombosis
deferasirox 45, *46*
deferiptone 45–6, *46*
deferoxamine 46
deletions *129*, 130
demethylation agents *141*, **142**, 144
dendritic cells 97, **98**, 109
neoplasms 226
deoxycoformycin **142**
deoxyhaemoglobin *17*
1-diamino-8-D-arginine vasopressin *see* DDAVP
Diamond-Blackfan syndrome 244, 247, **248**
differentiation syndrome 153
diffuse large B-cell lymphoma 223–4, *224*
cytogenetics **217**
immunophenotype **217**
dihydrofolate reductase *51*, 52
diploid cells 127
dipyridamole 287, 320
direct antiglobulin test (DAT) 340
disseminated intravascular coagulation 287, 297–300, *298*
clinical features 298–9, *299*
laboratory findings 299, **299**
pathogenesis 297–8, **298**
treatment 299–300, **300**
divalent metal transporter 1 *see* DMT-1
DMT-1 29, 30
DNA methylation *179*
DNA microarrays 131, *132*
DNA-binding domain 8
Döhle bodies *93*
Donath-Landsteiner antibody 69–70
donor leucocyte infusions 162, 253, 261, *262*
driver mutations 125, 147
drug interactions, oral anticoagulants 315, **316**, **317**
drug-induced disorders
aplastic anaemia **243**
haematological malignancies 124
immune haemolytic anaemias 70, *70*
neutropenia 95
platelet function 287, *288*
thrombocytopenia *281*, **281**, 284, *284*
Duffy blood group system **336**
duplications *129*, 130
dyskeratosis congenita 244

Eastern Cooperative Oncology Group (ECOG) Performance Status 136, **136**
echinocytes *23*
eculizumab 247
edoxaban **317**
Ehlers-Danlos syndrome 279
electrocardiogram in pulmonary embolus 308
elliptocytes *23*
elliptocytosis 19
hereditary **64**, 65, *65*
eltrombopag 246, 283, *284*
Embden-Meyerhof pathway 18, *18*
defects 67–8
endothelial cells 273, *274*
enteropathy-associated T-cell lymphomas 226
eosin-5-maleimide *65*
eosinophils **12**, 88, *88*, 90
blood count **20**, **88**
eosinophilic granuloma 98
eosinophilic leucocytosis (eosinophilia)
causes 96–7, *97*, **97**
myeloid neoplasms **166**
epigenetic changes *129*, 130–1
epigenetics 8–9, **8**, 130, 178
Epstein-Barr virus (EBV) 111–12
antibody 113
post-stem cell transplant 259

eptifibatide **319**, 320
erythroblasts *13*
erythrocyte sedimentation rate 330, 332
erythrocytes *see* red cells
erythrocytosis (primary polycythaemia) 168, **168**
erythropoiesis 11–26
  assessment of 25
  ineffective 24–5, *25*
erythropoietin 5, **6**, 13–16, *15*, 326
  clinical uses **16**
  and haemoglobin production *15*
  indications for therapy 16
  thrombocythaemia **172**
essential thrombocythaemia *see* thrombocythaemia
etoposide *141*, **142**
  BEACOPP regimen 211
ETV6-RUNX1 translocation 187
extramedullary haemopoiesis 118
extravascular haemolysis 63

18F-fluorodeoxyglucose *see* FDG
factor I 270, *273*, **273**
factor II **271**, **273**
factor IIa inhibitors **317**
factor III **271**, 272, 273, 275
factor V **271**, **273**
  deficiency 296
factor V Leiden mutation 304–5, *305*
factor VII **271**, **273**
  deficiency 296
  freeze-dried concentrates 344
  recombinant activated 294
factor VIII **271**, **273**, 293
  autoantibodies 300
  deficiency *see* haemophilia A
  inhibitors 294
  raised, in venous thrombosis 306
  recombinant 293
factor IX **271**, **273**
  deficiency *see* haemophilia B (Christmas disease)
factor IX-prothrombin complex concentrates 344–5
factor X **271**, **273**
  deficiency 296
factor Xa inhibitors **317**
factor XI **271**, **273**
  deficiency 296
factor XII **271**
factor XIII **271**, *273*, **273**
  deficiency 296
familial amyloidosis **238**
familial polycythaemia **75**
Fanconi anaemia 244, *244*, *245*
FDG-PET in Hodgkin lymphoma 209–10, *210*
FEIBA 300
Felty's syndrome *324*
ferrireductase 31
ferritin
  hyperferritinaemia **42**
  iron in **28**
  regulation 29
  serum levels **20**, 35, *36*
ferroportin 31, *32*
fertility in cancer patients 137
fetomaternal alloimmune thrombocytopenia 350
fetus/fetal
  haemoglobin **16**, 73, 74, 81
  sites of haemopoiesis **2**
  see also neonates
fibrin (factor I) 270, *273*, **273**
fibrin-stabilizing factor *see* factor XIII
fibrinogen **271**, 272–3
  defects 306
  quantitation **276**
  raised, in venous thrombosis 306
fibrinolysis 275–6, *276*
  tests of 277
fibrinolytic agents 318
  contraindications **319**
Fitzgerald factor (high molecular weight kininogen) **271**
Fletcher factor (prekallikrein) **271**
flow cytometry 131, *132*, 133
  ALL **189**
  platelet function 277
fludarabine *141*, **142**
  CLL 200
fluorescence *in situ* hybridization (FISH) 131, *131*
FOG-1 14
folate **50**, 51–2
  absorption, transport and function 51
  red cell **20**, **57**
  reduction 52
  serum **20**, **57**
  structure *51*
folate deficiency 53
  causes **53**
  clinical features 53–6, *54–6*, **54**
  diagnosis 56–7, **57**
  pregnancy 347
  tests for cause 57, **57**
  treatment 57–8, **57**, *58*
follicular lymphoma 222–3, *222*
  cytogenetics **217**
  immunophenotype **200**, **217**
fondaparinux 315
foscarnet 259
fresh frozen plasma (FFP) 344
fungal infections in cancer patients 139–40, *139*, *140*

G1 phase 8
G2 phase 8
ganciclovir 259
gastritis
  atrophic 35, 37, 53
  autoimmune 35, 52
GATA-2 4, 14
Gaucher's disease 99, *99*, *100*
gene segments 107, *107*
gene sequencing 131
gene therapy in haemophilia A 294
genetic markers 133–4, *133*, *134*
genetics
  ALL 189–91, *190*, *191*
  AML **146**, 149, *151*, **151**, *152*
  CML **166**
  haematological malignancies *124–7*, 125–7, **126**
  pre-implantation genetic diagnosis 85
germinal centre *111*
giant cavernous haemangioma 279
Gilbert's disease 64
glandular fever *see* infectious mononucleosis
Glanzmann's thrombasthenia 266, 287
glossitis 32, *54*
glucose-6-phosphate dehydrogenase deficiency 66–7, *66*, *67*
glutathione deficiency 67
glycophorin **147**
glycoprotein IIb/IIIa inhibitors **319**, 320
golf ball cells *77*
graduated compression stockings 318
graft-versus-host disease 256, 258
  acute 257, *258*, **258**
  chronic 258
  post-transfusion 342
graft-versus-leukaemia effect 261, *261*
granulocyte colony-stimulating factor (G-CSF) 5, **6**, 90
  clinical uses 91
  effects of *91*
granulocyte-macrophage colony-stimulating factor (GM-CSF) 90
granulocytes 88, 89–90, *89*
  concentrates 344
  see also specific types
granulopoiesis 90–1, *90*, *91*
growth factor receptors 6–8, *7*
growth factors 4–6, *5*, **5**, **6**

haem *16*, 30, *32*
haem enzymes **28**
haemangioblasts 2
haematinics, normal values **20**
haematocrit **20**
haematological malignancies 122–34, *123*, 135–44
  aetiology 124–5, *124*
  diagnostic methods 131–3, *131–3*
  ECOG status 136, **136**
  genetic abnormalities associated with 129–31, *129*, *130*
  genetic markers 133–4, *133*, *134*
  genetics *124–7*, 125–7, **126**
  incidence 123, *123*
  specific therapies 140–4, *141*, **142–3**
  supportive therapy 136–40
  see also specific therapies
haematoma **279**
haematopoietin receptor superfamily 6
haemochromatosis **42**, 43–4, *43*
haemoglobin 2, 13, 16–17, **16**, 73
  and erythropoietin production *15*
  fetal-adult switch 74
  function 17, *17*
  genetic disorders of 74–86, **75**
  hereditary synthesis disorders 68
  iron in **28**
  molecular aspects 73–4, *73*, *74*
  myelofibrosis **174**
  normal values *20*, **20**
  oxygen dissociation curve *17*, 20
  prenatal diagnosis of genetic disorders 85, *86*
  synthesis 16–17, *16*, *17*, 73
  thrombocythaemia **172**
  see also anaemia
haemoglobin A **16**, 73
haemoglobin A2 **16**, 73
haemoglobin Barts **75**, 76, *76*
haemoglobin C *80*, *84*, 85
haemoglobin Constant Spring 76
haemoglobin D 81, 85
haemoglobin E 81, 85
haemoglobin F **16**, 73, 81, 85
haemoglobin H *77*, *80*
haemoglobin Lepore 77, 81
haemoglobin S 17, *80*, 85
  see also sickle cell anaemia
haemoglobinaemia 63
haemoglobinuria 63, *64*
  march 70
  paroxysmal cold 69–70
  paroxysmal nocturnal 62, 246, 247, *247*
haemolysis **75**
haemolytic anaemias 60–71
  acquired 68–71
  autoimmune *see* autoimmune haemolytic anaemias
  classification 62, **62**
  clinical features 62, *63*
  hereditary 64–8
  intravascular/extravascular haemolysis 63, **63**, *64*
  laboratory findings 63
haemolytic disease of newborn 350–2, *351*, *352*
  ABO incompatibility 352
haemolytic transfusion reactions 340–2, **341**
haemolytic uraemic syndrome 285, *285*, *286*
  Rh incompatibility 350–2, *351*, *352*
haemophagocytic lymphohistiocytosis 98, *98*
haemophilia A 291–5
  antenatal diagnosis 291
  carrier detection 291
  clinical features 291, *292*, *293*
  disease severity **293**
  gene therapy 294
  laboratory findings 291, **294**
  molecular genetics 291, *291*, *292*
  prophylaxis 294
  treatment 293–4
haemophilia B (Christmas disease) 295
  disease severity **293**
  laboratory findings **294**, 295
haemopoiesis 1–10
  extramedullary 118
  regulation of 4, *7*, *91*
  sites of 2, *2*, **2**
  stem and progenitor cells 2–4, *3*
haemopoietic growth factors 4–6, *5–7*, **5**, **6**
  aplastic anaemia 247
haemopoietic progenitors 2, *3*
haemorrhage
  massive 345
  retinal *21*
haemorrhagic cystitis 260
haemorrhagic disease of newborn 296
haemosiderin 28
haemosiderinuria 63, 247
haemostasis *265*, 273–5
  disorders of 306
  haematological malignancies 137
  platelet plug 274–5
  pregnancy 348
  tests of 276–7, **276**
  vasoconstriction 273–4
  see also blood coagulation
Hageman (contact) factor *see* factor XII
hairy cell leukaemia 202–3, *203*
  cytogenetics **217**
  immunophenotype **200**, **217**
Hand-Schüller-Christian disease 98
haploid cells 127
haploidentical stem cell transplantation 256
haptoglobins 61
Heinz bodies *24*, 67, 71
Helicobacter pylori 33
  chronic idiopathic thrombocytopenic purpura 282
  haematological malignancies 125
  MALT lymphoma 221–2
  pernicious anaemia 52
hemojuvelin 30, 43
HEMPAS 249
Henoch-Schönlein syndrome 280, *280*
heparin 312–15, **313**
  administration and laboratory control 313–14
  bleeding during therapy 314
  haemostasis tests **299**
  indications 313
  low molecular weight **313**, 314
  mode of action 313, *313*
  osteoporosis 315
  unfractionated 313–14, **313**
heparin-induced thrombocytopenia 314–15, *314*
hepatitis, transfusion-related 338, **339**
hepcidin 29–30, *31*, 43
hereditary haemolytic anaemias 64–8
  elliptocytosis **64**, 65, *65*
  glucose-6-phosphate dehydrogenase deficiency 66–7, *66*, *67*
  South-East Asian ovalocytosis 65
  spherocytosis 64–5, **64**, *65*
hereditary haemorrhagic telangiectasia 279, *280*
herpes viruses 139
  post-stem cell transplant 259
  transfusion-related **339**
heterophile antibodies 112–13
hexose monophosphate shunt 18
HFE gene 43
high molecular weight kininogen (Fitzgerald factor) **271**
histiocytes 97, **98**
histiocytic cell neoplasms 226
HIV/AIDS
  cerebral lymphoma *224*, 225
  haematological changes 328, *329*
  transfusion-related 338, **339**

HLA system 255–6, *255*, **256**
inheritance *257*
and stem cell transplantation 256
HLA-restricted T cells 109
Hodgkin lymphoma 205–12
advanced stage 211
clinical features 206, *206*, *207*
diagnosis and histological classification 207, *207*, *208*, **208**
early stage 211
FDG-PET 209–10, *210*
haematological and biochemical findings 206–7
history and pathogenesis 206
late effects 212
prognosis **210**, 212
Reed-Sternberg cells *133*, 206, *207*
relapse 211–12
response to treatment 211
staging 208–9, *209*, **209**
treatment 210–12, **210**, *211*, *212*
WHO classification **208**
Howell-Jolly bodies *24*, *117*, 120
human albumin solution (4.5%) 344
human albumin solution (20%) 344
human leukocyte antigen *see* HLA
human T-cell leukaemia virus, transfusion-related 338
Hurler's syndrome 94
hydrops fetalis **75**, 76, *76*, 352, *352*
hydroxocobalamin **57**
hydroxodaunorubicin, CHOP regimen 223
hydroxycarbamide 85, *141*, **142**
polycythaemia vera 170, *171*
hydroxyurea *see* hydroxycarbamide
hypercalcaemia 237
hyperdiploid cells 127
ALL *190*, 191
hyperferritinaemia **42**
hyperglobulinaemia 287
hyperhaemolysis syndrome 342
hyperhomocysteinaemia 306
hypersplenism 119–20, **120**
hypertensive disorders, thrombocytopenia of 348
hyperviscosity syndrome 240, *240*
hypochromic anaemias 27–40, *28*
anaemia of chronic disorders 37, **37**, **38**
differential diagnosis **38**, 39
iron deficiency *see* iron deficiency anaemia
lead poisoning 39
sideroblastic anaemia 38–9, *38*, **39**
hypodiploid cells 127
ALL *190*, 191
hypomethylating agents 184
hyposplenism 120, **120**
infection prevention 121, **121**
hypothyroidism 327

ibritumomab **143**
ibrutinib **106**, *141*, **142**
CLL 201
mantle cell lymphoma 223
idarubicin **142**
idelasib **106**, **142**, 201
idiopathic acquired aplastic anaemia 244
idiopathic thrombocytopenic purpura (ITP) 282–3
acute 283
chronic 282–3
clinical features 282–3
diagnosis 283
pathogenesis 282, *282*
pregnancy 348
treatment 283
warm autoimmune haemolytic anaemia association 68–9, *69*
see also autoimmune thrombocytopenic purpura
Igs *see* immunoglobulins
imatinib *141*, **142**, 143, **160**
immune function, splenic control 117
immune haemolytic anaemias
alloimmune 70
autoimmune 68–70, *69*
drug-induced 70, *70*
immune response 109–11, *110*, *111*
immunity
adaptive 88
innate 88
immunodeficiency 113–14, **113**
see also HIV/AIDS
immunoglobulins 106–7, *106*, **106**
gene rearrangements 107, *107*, *108*
idiopathic thrombocytopenic purpura 283
IgA **106**
IgG **106**
IgM **106**
isotypes 106
pooled 345
replacement 202
subclasses 106
immunohistology (immunocytochemistry) 133, *133*
immunological markers **147**
immunological memory 103
immunoparesis 232
immunosuppressants in idiopathic thrombocytopenic purpura 283
indirect antiglobulin test (IAT) 340
infections 327–30, **327**, *328–30*
bacterial 327–8
cancer patients 138–9, *138*
haemolysis 71
hyposplenic patients 121, **121**
kala-azar (visceral leishmaniasis) 329, *330*
malaria 329, *329*
parasitic 329, *330*, *331*
post-stem cell transplant 258–60, *259*, *260*
and thrombocytopenia 283
toxoplasmosis 329
transfusion-related 338–9, **338**, **339**
viral 328
see also HIV/AIDS
infectious mononucleosis 111–12
inferior vena cava filter 318
inflammation, and venous thrombosis 306
innate immune system 88
interferon-α **143**, 144
chronic myeloid leukaemia 162
polycythaemia vera 171
interferon-γ 5
interleukins 5, **6**, 90
intermittent compression devices 318
international normalized ratio (INR) 315
interphase 8
interstitial pneumonitis 259, *260*
intravascular haemolysis 63, **63**, *64*
iron
absorption 30–1, **30**, *31*, *32*
body distribution/transport 28–30, **28**, *29*, *30*
daily cycle *29*
dietary 30
oral 36–7, **37**
parenteral 37
requirements 31–2, **33**
serum levels **20**, 34–5, *36*
iron chelation therapy 45–7, *46*, 79
aplastic anaemia 247
myelodysplasia 182
iron deficiency anaemia 32–7
blood film 34, *34*, *35*
causes 32–3, *33*, **33**
clinical features 32, *34*
investigations 35–6, *36*
laboratory findings **38**
pregnancy 347
red cell indices 34
treatment 36–7, **37**

iron overload 41–7
African 43
assessment 42, **42**, *43*
causes **42**
chelation therapy 45–7, *46*
haemochromatosis **42**, 43–4, *43*
transfusional 44, *44*, *45*, 342
iron refractory iron deficiency anaemia (IRIDA) 37
iron regulatory protein 29
iron response elements 29
isochromosome 129
ITP *see* idiopathic thrombocytopenic purpura

JAK inhibitors 171
JAK proteins 6, 8
JAK/STAT pathway 6
JAK2 mutation 166, *167*, **169**, **172**
Janus-associated kinase proteins *see* JAK proteins
juvenile myelomonocytic leukaemia 184

kala-azar (visceral leishmaniasis) 329, *330*
karyotype 127, *128*
analysis 131
Kell blood group system **336**, 337
kernicterus 351
Kidd blood group system **336**
kidney
myeloma *235*
renal failure 325–6, *325*, **325**
Kleihauer test 351, *351*
koilonychia 21, 32, *34*
Kupffer cells 275

labile factor *see* factor V
lactate dehydrogenase 286
Langerhans' cell histiocytosis 98, *98*, 226
large granular lymphocytic leukaemia 203–4, *203*
lazy leucocyte syndrome 93
lead poisoning 39
lenalidomide **143**
CLL 201
mantle cell lymphoma 223
multiple myeloma 236, 237
myelodysplasia 182
Lepore syndrome 77, 81
lestaurtinib 171
Letterer-Siwe disease 98
leucocyte adhesion molecules 92
leucocytes *see* white cells
leucodepletion 343
leucoerythroblastic reaction 94–5, *94*, **95**
leukaemia
acute lymphoblastic (ALL) 186–96
acute myeloid (AML) 145–55
acute promyelocytic 149, 152–3
chronic eosinophilic 164
chronic lymphoid 197–204
chronic myeloid (CML) 156–64, 184
chronic myelomonocytic 180, 184
chronic neutrophilic 164
classification 146, **146**
diagnosis 146–7, *146*, **147**
vs. lymphoma 214
see also specific types
leukaemoid reaction 94, 322
Lewis blood group system **336**, 337
Li blood group system **336**
liver disease 326–7, **326**
coagulation defects 297
haemostasis tests **299**
Loa loa 331
low molecular weight heparin **313**, 314
lupus anticoagulant 300–1
and venous thrombosis **307**
Lutheran blood group system **336**
lymph nodes *110*
lymphadenopathy 114, *114*
lymphoblastic lymphoma 225
lymphocytes **12**, 88, *88*, 102–15, *103*
antigen receptors *105*
B cells 103–4, *105*, **105**
blood count **20**, **88**
circulation 106
natural killer cells 104, 106
T cells 103–4, *105*, **105**
lymphocytosis 111–13, **111**
clinical features 112
diagnosis 112–13, *112*
differential diagnosis 113
heterophile antibodies 112–13
infectious mononucleosis 111–12
non-Hodgkin lymphoma 203
pleomorphic atypical 112, *112*
treatment 113
lymphoid organs 103, *104*
secondary 110
lymphoma
HIV/AIDS *224*, 225
Hodgkin *see* Hodgkin lymphoma
non-Hodgkin *see* non-Hodgkin lymphoma
T-cell 225–6
vs. leukaemia 214
see also specific types
lymphopenia 113
lymphoplasmacytic lymphoma
cytogenetics **217**
immunophenotype **217**
lymphoplasmacytoid lymphoma 221, *221*
lymphoproliferative diseases, post-transplant 261–2, *262*
lysosomal storage diseases 99–101
Gaucher's disease 99, *99*, *100*
Niemann-Pick disease 99, 101

M phase 8
macrocytes *23*
macrocytic anaemia 49, 58–9, **58**
see also megaloblastic anaemia
macrophage colony-stimulating factor (M-CSF) 5, **6**
macrophages 92
macrospherocytes *23*
magnetic resonance imaging *see* MRI
major histocompatibility complex (MHC) 256, **256**
see also HLA system
malaria 329, *329*
transfusion-related 338–9, **339**
malignancy
dendritic cells 226
haematological 122–34, *123*, 135–44
haematological changes 322–3, *323*, *324*, **324**
histiocytic cells 226
myelodysplastic/myeloproliferative 184, **184**
myeloid **166**
plasma cells **231**
and venous thrombosis 306
see also named diseases and tumours
malignant disease *see* neoplasms
MALT lymphoma 221–2, *222*
cytogenetics **217**
immunophenotype **217**
mantle cell lymphoma 223, *223*
cytogenetics **217**
immunophenotype **200**, **217**
MAP kinase 6
march haemoglobinuria 70
marginal zone lymphomas 221–2, *222*
massive haemorrhage 345
massive transfusion syndrome 287, 301
haemostasis tests **299**
mastocytosis 175, *175*
genetic mutations **166**
matriptase 2 30
May-Hegglin syndrome *93*, 94, 281
mean cell haemoglobin (MCH) **20**
mean cell volume (MCV) **20**, 21
megakaryocytes 182, 265–6, *266*, *267*

megaloblastic anaemia 49, **49**, *93*
biochemical basis *51*, 52
clinical features 53–6, *54–6*, **54**
laboratory findings 55–6, *55*, *56*
treatment 57–8, **57**, *58*
see also folate; vitamin B12
melphalan **142**
MTP regimen 235
multiple myeloma 235
men, iron requirements **33**
menorrhagia 33
6-mercaptopurine *141*, **142**
mesenchymal stem cells 4
methaemalbuminaemia 63
methaemoglobinaemia 17, **75**
methotrexate *141*, **142**
methylenetetrahydrofolate reductase 306
MGUS 229, **231**, *232*, 237–8, *238*
microangiopathic haemolytic anaemia *70*, 322
microcytes *23*
microRNAs 131
minor histocompatibility antigens 256
mitogen-activated protein kinase *see* MAP kinase
mitosis 8
mitoxantrone **142**
mixed phenotype acute leukaemia 148
MN blood group system **336**, 337
molecular genetics
ALL 189–91, *190*, *191*
AML **146**, 149, *151*, **151**, *152*
CLL 200
momelotinib 171
monoclonal antibodies *141*, **143**
idiopathic thrombocytopenic purpura 283
non-Hodgkin lymphoma 220
see also named antibodies
monoclonal B-cell lymphocytosis (MBL) 198
monoclonal gammopathy of undetermined significance *see* MGUS
monoclonal immunoglobulins, associated diseases **229**
monocyte colony-stimulating factor (M-CSF) 90
monocytes **12**, 88, *88*, 89, *89*, 92
blood count **20**, **88**
disorders of function 92–4, *92*, *93*
monocytosis 96, **97**
monospot test 112
MR pulmonary angiography 309
MRI
cerebral lymphoma *224*
deep vein thrombosis 308
haemophilia A *292*
non-Hodgkin lymphoma *219*
mucosa-associated lymphoid tissue lymphoma *see* MALT lymphoma
mucosal bleeding **279**
multiple myeloma 229–37
clinical features 231–2, *232–5*, *239*
diagnosis 231
pathogenesis 229, *230*, **231**
prognosis 237
relapse 237
smouldering 229, 231, **231**
supportive care 237
treatment 235, 233–7, *236*
Mycoplasma pneumoniae 328
mycosis fungoides 226, *226*
myeloablative conditioning 253
myeloblasts 89, *89*
myelodysplasia 91, 177–86
classification **178**, 179–80
clinical features 180, *182*
cytogenetic abnormalities **179**
diagnosis *181*
genetic abnormalities 182
high-risk syndromes 184
laboratory findings 180, *183*
low-risk syndromes 182
prognostic score **179**, **180**
treatment 182, 184
myelodysplastic syndromes *see* myelodysplasia
myelodysplastic/myeloproliferative neoplasms 184, **184**
myelofibrosis 173–5
clinical features 174
genetic mutations **166**, *167*
laboratory findings 174, *174*
survival score **174**
treatment 174–5
myeloid growth factors 90–1, *91*
myeloma *see* multiple myeloma
myeloma kidney *235*
myelomonocytic leukaemia
chronic 180, 184
juvenile 184
myeloproliferative disease 165–76, *166*, **166**, 287
JAK2 mutation 166, *167*
mastocytosis **166**, 175, *175*
myelofibrosis **166**, *167*, 173–5
polycythaemia 168–72
thrombocythaemia **166**, *167*, 172–3, **172**, *173*, **173**
Mylotarg® **143**
myoglobin, iron in **28**
nail bed pallor *21*
natural killer cells 104, 106
neonates 348–52
anaemia 349–50, *349*
blood coagulation 350
blood count **88**, 348–9, *349*
fetomaternal alloimmune thrombocytopenia 350
haemolytic disease of newborn 350–2, *351*, *352*
haemorrhagic disease of newborn 296
hydrops fetalis **75**, 76, *76*, 352, *352*
polycythaemia 350
neoplasms *see* malignancy
neural tube defects 55, *55*
neutropenia 91, 95–6
autoimmune 96
benign ethnic 95
causes **95**
clinical features 96, *96*
congenital 95
cyclical 95
diagnosis 96
drug-induced 95
HIV/AIDS 328
idiopathic benign 96
management 96
refractory **178**
neutrophil leucocytosis *93*, 94–5, *94*, **95**
causes **94**
neutrophils **12**, 88, *88*, 89, *89*
blood count **20**, **88**
disorders of function 92–4, *92*, *93*
precursors 89, *89*
Niemann-Pick disease 99, 101
nilotinib **142**, 143, **160**
nitric oxide 270
non-Hodgkin lymphoma 213–27
cell of origin 214, *216*
cellular origins *215*
classification 214, **214**, *215*
clinical features 216
cytogenetics/genetic analysis 217–18, **217**, *218*
high-grade 214, 223–5
histology 216, *217*
HIV/AIDS 328
imaging *219*, *220*
laboratory investigations 216–17
low-grade 214, 220–3
lymphocytosis 203
pathogenesis 216, **216**
prognostic index **218**
staging 218
T-cell lymphomas 225–6

non-Hodgkin lymphoma (*continued*)
treatment 220
see also specific subtypes
non-myeloablative conditioning 253
NOTCH signalling pathway 188
ALL *191*
NOTCH-1 4
nutritional support of cancer patients 137–8

O blood group **336**
obinutuzumab **143**, 201
oestrogen therapy, and venous thrombosis 307
ofatumumab **143**, 201
older patients
acute myeloid leukaemia 153
haematological changes 322
oncogenes 125
oral anticoagulants 315–18, **315–17**
bridging anticoagulation 316–17
direct acting 317–18, **317**
drug interactions 315, **316**
INR 315
length of anticoagulation 315
overdose 316, **316**
see also specific drugs
osteopetrosis 249
haematological changes 330
osteoporosis, heparin-induced 315
osteosclerotic myeloma (POEMS syndrome) 237
ovalocytosis, South-East Asian 65
oxyhaemoglobin *17*

P blood group system **336**, 337
packed cell volume (PCV) **20**
pacritinib 171
pain in haematological malignancies 138
pancytopenia 243, **243**
malignant disease **324**
Pappenheimer bodies *24*, *117*, 120
paraproteinaemia 107, 229, *229*
parasitic infections 329, *330*, *331*
transfusion-related **339**
paroxysmal cold haemoglobinuria 69–70
paroxysmal nocturnal haemoglobinuria 62, 246, 247, *247*
parvovirus B19 248
transfusion-related **339**
passenger mutations 125
Pearson's syndrome 38
PD-1 212
Pelger abnormality 180, *183*
Pelger-Huët anomaly *93*, 94
pencil cells *23*
pentose phosphate shunt 18
periarteriolar lymphatic sheath 117, *117*
peripheral blood stem cell (PBSC) transplantation 251
peripheral T-cell non-Hodgkin lymphoma, unspecified 225
pernicious anaemia 52–3
associations **53**
PET
Hodgkin lymphoma 209–10, *210*
multiple myeloma *233*
non-Hodgkin lymphoma *219*, *220*
petechiae **279**
PFA-100 test 277
coagulation disorders **294**
phagocytes **12**, 88
phagocytosis 92–3, *92*
defects 93
killing and digestion 93
Philadelphia (Ph) chromosome *157–8*, 191
phosphatidylinositol 3 kinase *see* PI3 kinase
PI3 kinase 6, 8
PIVKA factors 296
plasma cells *103*
neoplasms **231**
plasma cell leukaemia 237
plasma thromboplastin antecedent *see* factor XI
plasma viscosity 332
plasma volume **168**
plasmin 275
inactivation 276
plasminogen 275
platelets **12**, 265–70
adhesion *269*
aggregation 267–8, **294**
amplification 268
anaemia 22
antigens **147**, 266
concentrates 344
destruction 282–7
failed production 281, **281**
function 267–70
inhibitors of function 270
malignant disease 322–3, **324**
plug 274–5
procoagulant activity 268
production 265–6, *266*, *267*
release reaction 268
structure 266, *269*
transfusion 283, 289
platelet count **20**, 266
coagulation disorders **294**, **299**
myelofibrosis **174**
raised **173**
thrombocythaemia **172**
platelet function disorders 287–9
Bernard-Soulier syndrome 266, 287
diagnosis 288–9, *288*
drug-induced 287, *288*
Glanzmann's thrombasthenia 266, 287
hyperglobulinaemia 287
renal failure 326
storage pool diseases 287
uraemia 287
see also myeloproliferative disease
platelet function tests 277
platelet-derived growth factor (PDGF) 270, 303
platinum derivatives 144
pleomorphic atypical lymphocytosis 112, *112*
pletixafor 251
pluripotent stem cells 2–4, *3*
Pneumocystis carinii 259, *260*
POEMS syndrome (osteosclerotic myeloma) 237
point mutations 129, *129*
polycythaemia 168–72
apparent 172
classification 168, **168**
differential diagnosis 172
genetic mutations **166**, *167*
malignant disease 322
neonate 350
primary (erythrocytosis) 168, **168**
secondary **168**, 172
polycythaemia vera 168–71
clinical features 169–70, *169*, *170*
congenital causes 171
course and prognosis 171
diagnosis 169, **169**
genetic mutations **166**
laboratory findings 170, *170*
treatment 170–1, *171*
polymerase chain reaction (PCR) 134, *134*
pomalidomide **143**
multiple myeloma 235, 237
ponatinib **160**
positron emission tomography *see* PET
post-capillary venules 106
post-thrombotic syndrome 318
post-transfusion circulatory overload 342
post-transfusion purpura 284, 342
post-transfusional iron overload 44, *44*, *45*, 342
post-transplant lymphoproliferative diseases 261–2, *262*
postoperative venous thrombosis 306
prasugrel 287, 320
pre-implantation genetic diagnosis 85

prednisolone
ALL *189*
autoimmune haemolytic anaemia 68, 201
BEACOPP regimen 211
CHOP regimen 223
ITP 283, *284*
MTP regimen 235
R-CVP regimen 222
pregnancy 347–8, *347*, *348*
anaemia 347, *347*
folate/vitamin B12 deficiency 347
haemostasis and thrombosis 348
thrombocytopenia 347–8, *348*
prekallikrein (Fletcher factor) **271**
prenatal diagnosis in haemoglobin disorders 85, *86*
primary cold agglutinin disease 69–70
prion diseases, transfusion-related 339, **339**
procarbazine, BEACOPP regimen 211
proconvertin *see* factor VII
progenitor cells 2–4, *3*, 12–13
prolymphocytic leukaemia
B-cell 202, *202*
T-cell 203
promyelocytes 89, *89*
prostacyclin 268, 270, *270*
protein 4.1 19
protein C 275, *275*
concentrate 345
deficiency 305
protein S 275
deficiency 305–6
prothrombin allele G20210A 306
prothrombin (factor II) **271**, **273**
prothrombin time 276, **276**
coagulation disorders **294**, **299**
proto-oncogenes 125, *125*
protozoal infections
and haematological malignancies 125
transfusion-related **339**
see also malaria
pseudodiploid cells 127
pseudopolycythaemia 168
psychological support of cancer patients 137
pulmonary angiography 309
pulmonary embolus 308–9, *309*
prophylaxis 318
purpura 280, *280*, *281*
post-transfusion 284, 342
thrombotic thrombocytopenic 285, *285*, *286*
pyruvate kinase deficiency 67–8

5q-syndrome 180
R-CHOP regimen 223
R-CVP regimen 222–3
R-FC regimen 200
R-ICE regimen 224
radiation-induced disorders 124
radiography
ALL *189*
haemophilia A *292*
interstitial pneumonitis *260*
multiple myeloma *233*, *235*
pulmonary embolus 308
radionuclide scanning *239*
radiotherapy
CLL 201
multiple myeloma 237
rasburicase 137
RD regimen 235
reactive systemic AA amyloidosis **238**
recombinases 107
red cells **12**, 17–19
abnormalities *23*
amplification and maturation *14*
anaemia 21, **22**
antigens 334, **335**
destruction 61, *61*
DNA content *14*
erythrocyte sedimentation rate 330, 332
folate **20**, **57**
inclusions *24*
malignant disease **324**
membrane 18–19, *19*
metabolism 18, *18*
metabolism defects 66–8, *66*, *67*
packed 343, *343*
splenic control of integrity 117
volume **168**
red cell aplasia 247–9, *247*, **248**
red cell count **20**
red cell fragmentation syndromes 70, *70*, **70**
red cell indices
anaemia 21, 34
iron deficiency 34
normal **20**
red pulp of spleen 117, *117*
Reed-Sternberg cells *133*, 206, *207*
refractory anaemia **178**
with excess blasts **178**, 180
with ring sideroblasts (RARS) **178**
refractory cytopenia
with multilineage dysplasia (RCMD) **178**
with unilineage dysplasia (RCUD) **178**
refractory neutropenia **178**
refractory thrombocytopenia **178**
renal failure 325–6, *325*, **325**
reticulocytes *24*
reticulocyte count **20**
anaemia 22, **22**
reticuloendothelial system 61, *92*
retinal haemorrhage *21*
trans-retinoic acid **142**
Rh blood group system 335, **336**
genotypes **338**
haemolytic disease of newborn 350–2, *351*, *352*
molecular genetics *337*
rheumatoid arthritis, haematological changes 323–5, *324*
Rickettsia rickettsii **339**
ring sideroblasts 38, *38*, **178**, 180, *183*
rituximab **143**
CLL 200
idiopathic thrombocytopenic purpura 283
non-Hodgkin lymphoma 220
rivaroxaban **317**, 318
romiplostim 283
Rosai-Dorfmann disease 99
ROTEM (thromboelastometry) 277, 301
rouleaux formation *234*
ruxolitinib *141*, **142**
polycythaemia vera 171

schistosomiasis 329
Schwachman-Diamond syndrome 95, 244, 249
SCL 4
scurvy (vitamin C deficiency) 280, *280*
self-renewal 2, *3*, 4
senile purpura *280*
serum free light chain assay 232, *233*
Sézary syndrome 226
sicca syndrome 261
sickle cells *23*
sickle cell anaemia *80*, 81–5
antenatal diagnosis *86*
aplastic crises 83
clinical features 81–4, *82–4*
haemolytic crises 83
laboratory findings 84
molecular pathology *81*
organ damage 83–4, *83*, *84*
treatment 84–5
vaso-occlusive crises 82, *83*
sickle cell trait *80*, 85
sideroblastic anaemia 38–9, *38*, **39**
laboratory findings **38**
signal transducer and activator of transcription *see* STAT
signal transduction 6–8, *7*
signal transduction inhibitors **142**, 143

sinus histiocytosis with massive lymphadenopathy 99
slg **189**
small lymphocyte lymphoma 220
immunophenotype **217**
smouldering myeloma 229, 231, **231**
solitary plasmacytoma 237
somatic hypermutation 200
somatic mutation 107
South-East Asian ovalocytosis 65
spectrin 19
spherocytosis 19, *328*
hereditary 64–5, **64**, *65*
spleen 116–21
anatomy and circulation 117, *117*
atrophy *117*
cords of 117, *117*
enlarged *see* splenomegaly
extramedullary haemopoiesis 118
functions 117
hypersplenism 119–20
hyposplenism 120, **120**, 121, **121**
imaging 118, *118*, *119*
red pulp 117, *117*
white pulp 117, *117*
splenectomy 79, 120, **120**
idiopathic thrombocytopenic purpura 283
myelofibrosis 175
splenic pooling 287
splenomegaly 118–19, **120**
Felty's syndrome *324*
marginal zone lymphoma 222
myelofibrosis *174*
platelet distribution *286*
polycythaemia vera *169*
SRSF2 mutation 184
starry sky appearance *225*
STAT 6
stem cells
homing 4
mesenchymal 4
mobilization 4
pluripotent 2–4, *3*
stem cell transplantation 250–63
acute myeloid leukaemia 153
allogeneic *see* allogeneic stem cell transplantation
aplastic anaemia 246–7
autologous 254, *255*
bone marrow cells 251
chronic myeloid leukaemia 162, *163*
CLL 202
conditioning 253
haploidentical 256
idiopathic thrombocytopenic purpura 283
indications **251**
myelodysplasia 184
peripheral blood stem cells 251
post-transplant engraftment/immunity 253–4, *254*
potential donors **251**
principles 251, **251**
procedure *252*
stem cell processing 251, 253, *253*
umbilical cord blood cells 251
stercobilin 61
sterocobilinogen 61
steroid purpura 280
stomatocytes *23*
storage pool diseases 287
streptokinase 318
Stuart-Prower factor *see* factor X
subacute combined degeneration of cord 53, *54*, 55
superficial venous thrombosis 307
systemic amyloid light chain amyloid disease 238–9, **238**, *239*
systemic diseases, haematological changes 321–32
anaemia of chronic disorders 322, **322**
congestive heart failure 326
hypothyroidism 327
infections 327–30, **327**, *328–30*
liver disease 326–7, **326**
neoplasms 322–3, *323*
non-specific monitoring 330–2, **331**
older patients 322
osteopetrosis 330
renal failure 325–6, *325*, **325**
rheumatoid arthritis 323–5, *324*
systemic lupus erythematosus (SLE) 325

T cells 103–4
functional aspects **105**
HLA-restricted 109
immunodeficiency **113**
T-cell chronic lymphoid leukaemias 203–4
T-cell lymphomas 225–6
T-cell prolymphocytic leukaemia 203
T-cell receptor, gene rearrangements 107, *108*
T helper cells 110
target cells *23*
TdT **189**
tear drop poikilocytes *23*
telomerase 129
telomere 128, 129, *129*
TET2 mutation 127, 184
tetrahydrofolate 306
thalassaemias **75**
α-thalassaemia syndromes **75**, 76, *76*, *77*
β-thalassaemia major 76–9, *77*, *78*
β-thalassaemia minor 79, 81
classification **75**
δβ-thalassaemia 81
geographical distribution *75*
haemoglobin in 73, *74*
thalassaemia intermedia 43–4, **75**, 79–81, **79**, *80*, *81*
thalassaemia major *43*, *44*, **75**
thalassaemia trait **75**, 79, 81
laboratory findings **38**
thalidomide **143**
MTP regimen 235
multiple myeloma 236, 237
thrombasthenia 266, 287
thrombin 270–1, *272*
thrombin time 276, **276**
coagulation disorders **299**
thrombocythaemia 172–3
clinical features **172**, 173
course 173
diagnosis 172–3
genetic mutations **166**, *167*
laboratory findings **172**, 173, *173*, **173**
prognosis and treatment 173
survival **172**
thrombocytopenia 281–7
with absent radii 244
amegakaryocytic 244
antiphospholipid syndrome 307
causes **281**
drug-induced *281*, **281**, 284, *284*
fetomaternal alloimmune 350
haemolytic uraemic syndrome 285, *285*, *286*
heparin-induced 314–15, *314*
of hypertensive disorders 348
infection-related 283
liver disease 297
malaria 329, *329*
massive transfusion syndrome 287, 301
platelet destruction 282–7
platelet function disorders 287–9
platelet production failure 281, *281*, **281**
post-transfusion purpura 284, 342
pregnancy 347–8, *348*
refractive **178**
splenic pooling 287
thrombomimetics 289
viral infections 328
thrombocytopenic purpura, autoimmune 282–3, *282*

thromboelastography 277, *300*, 301
thromboelastometry 277, 301
thrombolytic therapy 287, 318–20, *319*, **319**
thrombomimetics 289
thrombophilia 307–8
thrombopoietin (TPO) 5, **6**, 265, *268*
thrombopoietin-receptor agonists 283
thrombosis 302–10, 311–20
  anticoagulants 312–18
  antiplatelet drugs 318–20, *319*, **319**
  arterial 303, *303*, **303**
  fibrinolytic agents 318
  older patients 322
  post-thrombotic syndrome 318
  pregnancy 348
  prophylaxis 318
  venous *see* venous thrombosis
thrombotic thrombocytopenic purpura 285, *285*, *286*
thromboxane A2 268, *270*
ticragelor 320
tirofiban **319**, 320
tissue factor *see* factor III
tissue factor pathway inhibitor (TFPI) 272
tissue plasminogen activator (TPA) 275, *276*, 318
tissue plasminogen activator inhibitor (TPAI) *275*
total iron-binding capacity **20**, 34–5, *36*
toxoplasmosis 329
trabecular arteries 117, *117*
tranexamic acid 280
transcobalamins 49
transcription factors 8
transferrin 28, **28**
  regulation 29
transferrin receptor 1 regulation 29, *30*
transforming growth factor-β 5
transfusion reactions 340–2, **341**
transfusion-related acute lung injury (TRALI) 342
transfusional iron overload 44, *44*, **44**, *45*
translocations 129–30, *129*, *130*
treosulfan 253
Treponema pallidum **339**
tropical splenomegaly syndrome 119
trypanosomiasis 329, *330*
tuberculosis 328
tumour lysis syndrome 137
tumour necrosis factor (TNF) 5, **6**, 90, 256
tumour-suppressor genes 125
tyrosine kinase inhibitors *141*, **142**
  chronic myeloid leukaemia 160–1, *160*, **160**, *161*
  response to therapy 160–2, *160–2*, **162**
  see also individual drugs
tyrosine kinases 125

ultra-large von Willebrand factor multimers 285, *285*
umbilical cord cell transplantation 251
uraemia 287

vaccination of hyposplenic patients 121, **121**
vascular bleeding disorders 279–80, **279**
  acquired 279–80
  connective tissue disorders 279
  giant cavernous haemangioma 279
  hereditary haemorrhagic telangiectasia 279, *280*
vascular endothelial growth factor (VEGF) **6**
vasoconstriction 273–4
VCD regimen 235
venesection in polycythaemia vera 170
venous stasis 306
venous thrombosis 303–7
  acquired risk factors 306–7, **307**
  deep vein thrombosis 308, **308**
  hereditary risk factors 304–6, **304**
  pathogenesis 303–4
  postoperative 306
  pulmonary embolus 308–9, *309*
  superficial 307
ventilation perfusion scintigraphy 309
vinblastine **142**
vinca alkaloids *141*, **142**, 143
vincristine **142**
  BEACOPP regimen 211
  CHOP regimen 223
  R-CVP regimen 222
viral infections
  cancer patients 139
  haematological changes 328
  and haematological malignancies 124–5
  post-stem cell transplant 259, *259*, *260*
  post-transfusion hepatitis 338, **339**
  transfusion-related 342
  see also HIV/AIDS
vitamin B12 49–51, *49*
  absorption 49, *50*, **50**
  biochemical function 51, *51*
  neuropathy 53, *54*, 55
  prophylactic 58
  serum **20**, **57**
  transport 49
vitamin B12 deficiency 52–3
  causes **52**, 53
  clinical features 53–6, *54–6*, **54**
  diagnosis 56–7, **57**
  pregnancy 347
  tests for cause 57, **57**
  treatment 57–8, **57**, *58*
vitamin C deficiency (scurvy) 280, *280*
vitamin K antagonists 315–18, **315–17**
vitamin K deficiency 296–7, *297*
von Willebrand disease 295–6
  classification **295**
  laboratory findings **294**, 295
  treatment 295–6
von Willebrand factor 266, 267, *269*, 295
  ultra-large 285, *285*
VRD regimen 235
VTD regimen 235

Waldenström's macroglobulinaemia 221, *221*
warfarin **317**
  drug interactions 315, **316**
  haemostasis tests **299**, **315**
  overdose 316, **316**
  vitamin K deficiency 296
warm autoimmune haemolytic anaemias 68–9, *69*
Weibel-Palade bodies 267, 285
white cells 87–101, 102–15
  abnormal *93*
  anaemia 22
  antibodies 342
  donor leucocyte infusions 162, 253, 261, *262*
  malignant disease 94, 322, **324**
  see also specific types
white cell count **20**, **88**
  myelofibrosis **174**
  thrombocythaemia **172**
white pulp of spleen 117, *117*
WHO classification **208**, 354–6
Wilson's disease 71, 326
Wiskott-Aldrich syndrome 95, 281
women
  iron requirements **33**
  pregnancy 347–8, *347*, *348*
Wuchereria bancrofti 331

X-ray *see* radiography

Yersinia enterocolitica **339**

Zieve's syndrome *325*, 326